Mitochondrial diseases are primarily genetic disorders that are essential for encoding proteins involved in mitochondrial function and generating energy as ATP through oxidative phosphorylation (OXPHOS). This causes mitochondrial dysfunction and energy deficits in the cell, affecting organs and tissues with high energy demands (e.g., the heart, kidneys, brain, eyes, and skeletal muscle). Passed from mother to child, mitochondrial diseases affect 1 in 5,000-10,000 children. On the rise, however, there are reproductive technologies that allow the replacement of defective mitochondrial DNA with healthy donor mitochondria. While there are concerns about safety and efficacy, and questions about legality, regulations, and ethics, I am for the use of mitochondrial DNA replacement therapy under proper circumstances.   

Mitochondrial DNA replacement therapy, as described above, substitutes mutated mitochondrial DNA with a new, functional copy. This replacement occurs in unfertilized oocytes and zygotes, essentially correcting the defect before engineering the child’s entire genome during pregnancy. One technique used in mitochondrial replacement therapy is spindle transfer (ST), which involves removing the spindle from a mature oocyte and inserting it into an enucleated donor egg. A new, healthy egg free of mutated mitochondrial DNA is constructed and is ready to be fertilized and transferred back to the patient.  

While there is promise for treating inherited diseases, there are also valid questions and concerns. Some current issues cite the possibility of procedural failure and of abnormalities arising from mismatches between nuclear and mitochondrial genomes. Another is the lack of proper global guidelines that ensure the safety and effectiveness of these procedures. Also, there is a genetic connection to three parents: mother, father, and mitochondrial donor, which might make it misleading for the child. Qualified as germ-line therapy, this is still new and experimental. This means trials are ongoing, and there is limited data on the long-term effects. It is a highly controversial topic that needs to be discussed; however, if done right, it can cure otherwise untreatable diseases.   

Despite unease, addressing these questions ensures safe and responsible technology use. Research suggests that failures, such as carryover of mutated mitochondrial DNA, are minimal, and primate studies show long-term compatibility with no abnormalities. Ongoing efforts in countries like England, the US, and Japan are assessing safety and effectiveness. I believe that—with the right research, regulations, and guidelines—mitochondrial DNA replacement therapy gives families a crucial option to break the cycle of inherited disease. Its promise outweighs uncertainties when it can prevent serious health problems in children. 

References

Di Donfrancesco, Alessia, et al. “Gene Therapy for Mitochondrial Diseases: Current Status and Future Perspective.” Pharmaceutics, vol. 14, no. 6, June 2022, p. 1287. https://doi.org/10.3390/pharmaceutics14061287.

Mitalipov, Shoukhrat, and Don P. Wolf. “Clinical and Ethical Implications of Mitochondrial Gene Transfer.” Trends in Endocrinology and Metabolism, vol. 25, no. 1, Dec. 2013, pp. 5–7. https://doi.org/10.1016/j.tem.2013.09.001.

Sendra, Luis, et al. “Mitochondrial DNA Replacement Techniques to Prevent Human Mitochondrial Diseases.” International Journal of Molecular Sciences, vol. 22, no. 2, Jan. 2021, p. 551. https://doi.org/10.3390/ijms22020551.

Sharma, Hitika, et al. “Development of Mitochondrial Replacement Therapy: A Review.” Heliyon, vol. 6, no. 9, Sept. 2020, p. e04643. https://doi.org/10.1016/j.heliyon.2020.e04643.

Yamada, Mitsutoshi, et al. “Mitochondrial Replacement by Genome Transfer in Human Oocytes: Efficacy, Concerns, and Legality.” Reproductive Medicine and Biology, vol. 20, no. 1, Nov. 2020, pp. 53–61. https://doi.org/10.1002/rmb2.12356.